Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

12 hours ago 1

Jonathan Ponciano, The Motley Fool

Sat, February 14, 2026 astatine 10:07 AM CST 4 min read

On February 13, 2026, Affinity Asset Advisors disclosed a acquisition of 61,500 shares of Apogee Therapeutics (NASDAQ:APGE), an estimated $3.87 cardinal commercialized based connected quarterly mean pricing.

According to an SEC filing dated February 13, 2026, Affinity Asset Advisors, LLC accrued its presumption successful Apogee Therapeutics by 61,500 shares during the 4th fourth of 2025. The estimated transaction value, based connected the mean closing terms for the quarter, was $3.87 million. Meanwhile, the fund's quarter-end involvement roseate to 1,234,926 shares, with the worth of the presumption expanding by $46.59 cardinal including some stock additions and terms appreciation.

Top 5 holdings aft the filing:
- NASDAQ: APGE: $93.21 cardinal (6.9% of AUM)
- NASDAQ: INSM: $78.32 cardinal (5.8% of AUM)
- NASDAQ: ABVX: $68.10 cardinal (5.0% of AUM)
- NASDAQ: VTYX: $58.56 cardinal (4.3% of AUM)
- NASDAQ: XENE: $56.02 cardinal (4.1% of AUM)
As of February 13, 2026, shares of Apogee Therapeutics were priced astatine $67.78, up 86.9% implicit the past year, with 75.14 percent points of alpha versus the S&P 500.

Metric

Value

Market capitalization	$4 billion
Net income (TTM)	($253.67 million)
Price (as of marketplace adjacent 2/13/26)	$67.78

Apogee Therapeutics develops biologic therapies, including monoclonal antibodies specified arsenic APG777 for atopic dermatitis and APG808 for chronic obstructive pulmonary disease, with further pipeline candidates targeting inflammatory and immunology indications.
The institution operates a research-driven biotechnology exemplary focused connected advancing proprietary biologics from early-stage improvement done objective trials, aiming for regulatory support and aboriginal commercialization.
It targets patients with chronic inflammatory and immunological diseases, with superior customers expected to beryllium healthcare providers, hospitals, and specialty clinics treating these conditions.

Apogee Therapeutics is simply a clinical-stage biotechnology institution specializing successful the improvement of extended half-life monoclonal antibodies for the attraction of atopic dermatitis, COPD, and related inflammatory diseases. The company's strategy centers connected leveraging proprietary biologic platforms to code important unmet aesculapian needs successful immunology. With a focused pipeline and a scalable attack to biologics development, Apogee aims to found a competitory presumption successful the specialty therapeutics market.

This determination has the hallmarks of a high-conviction biotech stake connected a sanction that’s surely showing immoderate momentum. In the firm's latest quarterly report, released past month, Apogee CEO Donald Nolan said helium was "proud" of the firm's "disciplined execution" contempt a "challenging environment." The Apogee presumption present totals 1,234,926 shares valued astatine $93.21 million, oregon 6.9% of reportable assets. The holding climbed $46.59 cardinal successful worth during the period, acknowledgment to a steep ascent passim the quarter. And with the banal delivering astir 75 percent points of alpha versus the S&P 500, this is nary tiny bet.

More broadly, the portfolio is concentrated successful clinical-stage biotech names specified arsenic Insmed, Abivax, Ventyx, and Xenon, each betwixt 4% and 6% of assets. Apogee present sits astatine the apical of that cluster, suggesting differentiated assurance successful its monoclonal antibody pipeline targeting atopic dermatitis and COPD.

Ultimately, semipermanent investors should retrieve what drives outcomes here. Clinical data, regulatory milestones, and superior subject substance much than short-term volatility.

Read Entire Article